You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Diffuse Large B Cell Lymphoma CNS High Grade

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Not yet recruiting
  • Lymphoma, B-Cell
  • +6 more
  • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
  • Guayaquil, Guayas, Ecuador
    Instituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis, Saint Louis (FT596, Rituximab)

Suspended
  • NHL
  • +3 more
  • Minneapolis, Minnesota
  • +1 more
Jan 31, 2023

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

Available
  • Large B-cell Lymphoma
  • +4 more
  • Epcoritamab
  • (no location specified)
Feb 16, 2023

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Mitoxantrone hydrochloride liposome injection
    • +4 more
    • Changchun, Jilin, China
      The First Bethune Hospital of Jilin University
    Aug 15, 2023

    Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

    Not yet recruiting
    • Recurrent ALK Positive Large B-Cell Lymphoma
    • +28 more
    • Biospecimen Collection
    • +5 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 17, 2022

    Predict CNS Involvement in Diffuse Large B-Cell Lymphoma:Danish

    Completed
    • Diffuse Large B Cell Lymphoma
    • +2 more
      • (no location specified)
      Dec 13, 2021

      Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

      Recruiting
      • Diffuse Large B-cell Lymphoma Recurrent
      • Diffuse Large B Cell Lymphoma Refractory
      • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
      • Hangzhou, Zhejiang, China
        Zhejiang Cancer Hospital
      Oct 12, 2023

      Multiple Myeloma (MM), DLBCL, Not Otherwise Specified, Double Hit Lymphoma Trial in Spain (IDP-121)

      Recruiting
      • Multiple Myeloma (MM)
      • +5 more
      • Santander, Cantabria, Spain
      • +4 more
      Jun 19, 2023

      DLBCL, DLBCL Germinal Center B-Cell Type, DLBCL, Not Otherwise Specified Trial in Columbus (Molecular Nanotechnology)

      Recruiting
      • Diffuse Large B-Cell Lymphoma
      • +3 more
      • Molecular Nanotechnology
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Jun 2, 2022

      Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

      Recruiting
      • Recurrent Diffuse Large B-Cell Lymphoma
      • Refractory Diffuse Large B-cell Lymphoma
      • RC19D2 cell injection
      • Tianjin, Tianjin, China
        Hematology Hospital of the Chinese Academy of Medical Sciences
      Sep 14, 2023

      Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
      • (no location specified)
      Sep 5, 2023

      B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

      Recruiting
      • B-Cell Non-Hodgkin Lymphoma
      • +7 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Dec 9, 2022

      Lymphoma, Lymphoma, Large B-Cell, Diffuse Trial in Boston (Glofitamab, Polatuzumab, Rituximab)

      Not yet recruiting
      • Lymphoma
      • Lymphoma, Large B-Cell, Diffuse
      • Boston, Massachusetts
      • +1 more
      Apr 4, 2023

      Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

      Not yet recruiting
      • Lymphoma, B-Cell
      • +7 more
      • Adaptive Bridging Radiation Therapy (ABRT)
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      Aug 16, 2023

      Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

      Active, not recruiting
      • Relapsed or Refractory Diffuse Large B-cell Lymphoma
      • BEBT-908 for injection
      • Beijing, China
        Cancer Hospital Chinese Academy of Medical Sciences
      Oct 8, 2023

      Cardiovascular Events Among Adults Relapsed or Refractory

      Recruiting
      • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
      • +9 more
      • Electronic Health Record Review
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 5, 2022

      DLBCL Trial (Polatuzumab Vedotin)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • Polatuzumab Vedotin
      • (no location specified)
      Jul 12, 2023

      Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Zanubrutinib, Polatuzumab vedotin and Rituximab
      • Shanghai, Shanghai, China
        Zhongshan Hospital，Fudan University
      Jul 10, 2023